← All Imunon, INC filings

Imunon, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
IMNN
Imunon, INC
10-K: Imunon Reports Strong Ovarian Cancer Data, Faces Going Concern
Imunon, Inc. announced positive final Phase 2 data for its lead ovarian cancer immunotherapy, IMNN-001, showing significant overall survival benefits, but also disclosed substantial doubt about its ability to continue as a going concern.
NASDAQ
IMNN
Imunon, INC
10-K: Imunon's 10-K Filing Reveals Ongoing Losses and Focus on Ovarian Cancer Immunotherapy
Imunon's 10-K filing highlights the company's continued losses, its focus on the IMNN-001 ovarian cancer immunotherapy program, and its next-generation vaccine initiative.
NASDAQ
IMNN
Imunon, INC
10-K: Imunon Inc. Files 10-K Report, Outlines Progress in Immunotherapy and Vaccine Development
Imunon Inc.'s 10-K filing details the company's financial status, ongoing clinical trials, and advancements in its immunotherapy and vaccine platforms.